PMID- 38239353
OWN - NLM
STAT- MEDLINE
DCOM- 20240122
LR  - 20240402
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 14
DP  - 2023
TI  - Role of MCP-1 as an inflammatory biomarker in nephropathy.
PG  - 1303076
LID - 10.3389/fimmu.2023.1303076 [doi]
LID - 1303076
AB  - The Monocyte chemoattractant protein-1 (MCP-1), also referred to as chemokine 
      ligand 2 (CCL2), belongs to the extensive chemokine family and serves as a 
      crucial mediator of innate immunity and tissue inflammation. It has a notable 
      impact on inflammatory conditions affecting the kidneys. Upon binding to its 
      receptor, MCP-1 can induce lymphocytes and NK cells' homing, migration, 
      activation, differentiation, and development while promoting monocytes' and 
      macrophages' infiltration, thereby facilitating kidney disease-related 
      inflammation. As a biomarker for kidney disease, MCP-1 has made notable 
      advancements in primary kidney diseases such as crescentic glomerulonephritis, 
      chronic glomerulonephritis, primary glomerulopathy, idiopathic proteinuria 
      glomerulopathy, acute kidney injury; secondary kidney diseases like diabetic 
      nephropathy and lupus nephritis; hereditary kidney diseases including autosomal 
      dominant polycystic kidney disease and sickle cell kidney disease. MCP-1 not only 
      predicts the occurrence, progression, prognosis of the disease but is also 
      closely associated with the severity and stage of nephropathy. When renal tissue 
      is stimulated or experiences significant damage, the expression of MCP-1 
      increases, demonstrating a direct correlation with the severity of renal injury.
CI  - Copyright (c) 2024 Liu, Xu, Xiang, Ma, Li, Li, Shi, Li and Bai.
FAU - Liu, Yanlong
AU  - Liu Y
AD  - Heilongjiang Provincial Health Commission, Harbin, China.
FAU - Xu, Ke
AU  - Xu K
AD  - Heilongjiang University of Chinese Medicine, The Second Clinical Medical College, 
      Harbin, China.
FAU - Xiang, Yuhua
AU  - Xiang Y
AD  - Heilongjiang Academy of Traditional Chinese Medicine, Harbin, China.
FAU - Ma, Boyan
AU  - Ma B
AD  - Heilongjiang University of Chinese Medicine, The Second Clinical Medical College, 
      Harbin, China.
FAU - Li, Hailong
AU  - Li H
AD  - Heilongjiang Academy of Traditional Chinese Medicine, Harbin, China.
FAU - Li, Yuan
AU  - Li Y
AD  - The First Affiliated Hospital of Harbin Medical University, Harbin, China.
FAU - Shi, Yue
AU  - Shi Y
AD  - Heilongjiang University of Chinese Medicine, The Second Clinical Medical College, 
      Harbin, China.
FAU - Li, Shuju
AU  - Li S
AD  - Heilongjiang Academy of Traditional Chinese Medicine, Harbin, China.
FAU - Bai, Yan
AU  - Bai Y
AD  - Heilongjiang Academy of Traditional Chinese Medicine, Harbin, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240104
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Chemokine CCL2)
RN  - 0 (Biomarkers)
SB  - IM
MH  - Humans
MH  - Chemokine CCL2/metabolism
MH  - *Glomerulonephritis/diagnosis
MH  - *Lupus Nephritis/diagnosis
MH  - *Diabetic Nephropathies
MH  - Biomarkers
MH  - Inflammation
PMC - PMC10794684
OTO - NOTNLM
OT  - MCP-1
OT  - hereditary nephropathy
OT  - inflammatory markers
OT  - primary nephropathy
OT  - secondary nephropathy
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2024/01/19 06:42
MHDA- 2024/01/22 06:42
PMCR- 2023/01/01
CRDT- 2024/01/19 03:38
PHST- 2023/09/27 00:00 [received]
PHST- 2023/12/12 00:00 [accepted]
PHST- 2024/01/22 06:42 [medline]
PHST- 2024/01/19 06:42 [pubmed]
PHST- 2024/01/19 03:38 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2023.1303076 [doi]
PST - epublish
SO  - Front Immunol. 2024 Jan 4;14:1303076. doi: 10.3389/fimmu.2023.1303076. 
      eCollection 2023.